56. Behcet disease
68 clinical trials,   87 drugs   (DrugBank: 31 drugs),   36 drug target genes,   113 drug target pathways

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03371095
(ClinicalTrials.gov)
March 15, 20187/12/2017Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseMulticenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFa vs Cyclophosphamide in Severe Behçet DiseaseBehcet's Disease;VasculitisDrug: Infliximab;Drug: CyclophosphamideAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting12 YearsN/AAll52Phase 3NULL
2JPRN-UMIN000025451
2017/04/0128/12/2016Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's diseaseClinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease - Clinical studies on discontinuation of infliximab and making the shift to cyclosporine for refractory uveitis of Behcet's disease refractory uveitis of Behcet's diseasePatients with Behcet's disease who has received Infliximab intravenous infusion treatment at 8 week intervals over a long period (over 4 years) and calm eye inflammation, shall be discontinued from infliximab and be changed to cyclosporine A oral administration. For cases in which uveitis can not be suppressed and infliximab is reintroduced, if it is 20% or less, it shall be acceptable. Cyclosporine A is started orally at 5 mg / kg / day orally twice a day from 6 weeks after the final Infiximab administration, the maintenance dose is 3 to 5 mg / kg / day, and if the clinical findings are stabilized, Losing weight little by little is judged by the research doctor . The target trough value should be less than 150 ng / ml. The observation period of cyclosporine administration is one year.Yokohama City University HospitalNULLPending20years-old65years-oldMale and Female5Not selectedJapan
3EUCTR2014-005390-36-GB
(EUCTR)
17/02/201631/12/2015BIO BEHCET'S TRIALOptimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab (IFX) verses alpha interferon (aIFN), with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment. - BIO BEHÇET’S Behcets Disease
MedDRA version: 18.1;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Remicade
Product Name: Remicade
Product Code: 3400935113276
INN or Proposed INN: infliximab
Trade Name: Roferon-A, 3miu
Product Name: Roferon-A 3miu
Product Code: 8699505952864
INN or Proposed INN: alpha interferon
Trade Name: Roferon-A, 4.5miu
Product Name: Roferon-A, 4.5miu
Product Code: J1081
INN or Proposed INN: alpha interferon
Trade Name: Roferon-A, 6miu
Product Name: Roferon-A, 6miu
Product Code: 2387066
INN or Proposed INN: alpha interferon
The University of LiverpoolNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
100Phase 3United Kingdom
4NCT02505568
(ClinicalTrials.gov)
July 22, 201529/6/2015A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's DiseaseAn Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's DiseaseBehcet DiseaseDrug: InfliximabJanssen Korea, Ltd., KoreaNULLCompleted19 Years75 YearsAll33Phase 3Korea, Republic of
5NCT02620618
(ClinicalTrials.gov)
January 201326/11/2015Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical StudyIntravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical StudyBehçet's Disease;UveitisDrug: Intravitreal InfliximabCairo UniversityNULLCompletedN/AN/ABoth20Phase 1;Phase 2NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-002264-41-FR
(EUCTR)
19/07/2017NA Etude randomisée multicentrique évaluant l’efficacité et la tolérance de l’infliximab comparativement au Cyclophosphamide dans les formes sévères de maladie de Behçet Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Infliximab to that of Cyclophosphamide in severe Behçet's disease - ITAC Induction Therapy with Anti-TNF vs Cyclophosphamide in severe Behçet disease
MedDRA version: 20.0;Level: LLT;Classification code 10004212;Term: Behcet's disease;System Organ Class: 100000017240 ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLNA Female: yes
Male: yes
52Phase 2France